Insulin resistance is associated with poor functional outcome after acute ischemic stroke in non-diabetic patients

Yoonkyung Chang\textsuperscript{1,4}, Chi Kyung Kim\textsuperscript{2,4}, Min-Kyung Kim\textsuperscript{2}, Woo-Keun Seo\textsuperscript{3} & Kyungmi Oh\textsuperscript{*}

Insulin resistance is associated with the occurrence of stroke and atherosclerotic disease. However, the relationship between insulin resistance and the prognosis of acute ischemic stroke in non-diabetic patients is unclear. We hypothesized that insulin resistance might affect short-term functional recovery after acute ischemic stroke in non-diabetic patients. Between May 2014 and December 2016, 1377 consecutive patients with acute ischemic stroke were enrolled from a prospectively maintained stroke registry. After excluding patients with transient ischemic attacks (TIA), pre-stroke disabilities, diabetes mellitus, and patients with incomplete evaluations, 517 patients were included in the study. The homeostasis model assessment of insulin resistance (HOMA-IR) score was used to evaluate the degree of insulin resistance. The patients with the highest quartile of log HOMA-IR index scores were younger and had higher fasting blood glucose, total cholesterol, triglycerides, low-density lipoprotein, and HbA1c levels. Multivariable logistic regression analysis revealed that log HOMA-IR scores were independently associated with poor prognosis after adjusting for age and sex and \( p < 0.1 \) in univariable analysis. Insulin resistance was associated with the poor functional outcome of non-diabetic stroke patients. This evidence supports treating insulin resistance in acute ischemic stroke patients with blood glucose levels within the normal range.

Insulin resistance is defined as the loss of insulin effects on target tissues, observed in patients with type 2 diabetes mellitus\textsuperscript{1,2}. Insulin resistance results in impaired glucose utilization and increases hepatic glucose production. Among biomarkers of insulin resistance, the homeostasis model assessment-insulin resistance (HOMA-IR) index is an easy way to assess insulin resistance and is frequently used in epidemiologic studies\textsuperscript{3}. The role of insulin in the central nervous system is an active research field. Studies have been published showing the association between insulin resistance and neurocognitive dysfunction\textsuperscript{4,5}. In diabetic patients, the risk of dementia including Alzheimer’s disease increases\textsuperscript{6–9}. There are several roles of insulin and isolate resistance in the adult brain. Central nervous system insulin resistance causes diabetes and obesity through metabolic pathway homeostasis disruption\textsuperscript{6,11}. There are also studies showing that insulin resistance affects the synaptic plasticity of the neuron\textsuperscript{12}.

Meanwhile, it has long been known that hyperglycemia in stroke patients is associated with disease progression, neurologic deterioration and poor functional outcome\textsuperscript{13,14}. Stroke treatment guidelines recommend adjusting blood sugar level to a normal range\textsuperscript{15}, but treatment or assessment has not yet been recommended for insulin resistance. Recent studies have suggested that there is a strong relationship between insulin resistance and ischemic stroke. Insulin resistance has been reported to be associated with poor clinical outcomes after IV thrombolytic treatment\textsuperscript{16,17}. Pioglitazone, a peroxisome proliferator-activated receptor-\( \gamma \) agonist formerly used in diabetic patients, improved insulin sensitivity and recurrent cardiovascular disease in patients with ischemic strokes or transient ischemic attacks\textsuperscript{8,19}. Recently developed antidiabetic SGLT2 inhibitor, which affects insulin resistance\textsuperscript{20,21}, was also confirmed to have a cardioprotective effect in diabetic patients\textsuperscript{22}. A recent study in China reported that insulin resistance was associated with poor 1-year outcomes after acute ischemic strokes\textsuperscript{23}. However,
the reason for and mechanism of the association between insulin resistance and the prognosis of stroke patients has not been fully identified.

**Aim**  
This study hypothesized that insulin resistance might affect short-term functional recovery after acute ischemic strokes in non-diabetic patients. We aimed to determine whether this relationship was affected by stroke severity, stroke subtype, and clinical course.

**Methods**

**Subjects.** Between May 2014 and December 2016, 1377 patients with acute ischemic strokes within 7 days from symptom-onset were enrolled from a prospectively maintained stroke registry at our institution. In these 1377 patients, patients with transient ischemic attacks (TIA, n = 301) and pre-stroke disabilities (mRS score ≥ 2, n = 71) were excluded. After excluding the diabetic patients (n = 334) and those without 3 months of functional outcome data (n = 98) or insulin levels (n = 56), 517 patients were enrolled in the study (Fig. 1). This study was approved by the Institutional Review Board of our institution. Patient consent was waived due to the retrospective registry-based nature of the study.

**Insulin resistance.** Fasting glucose and insulin levels were measured within 24 h of admission after an 8 h fast. Glucose level was measured using a Hitachi 747 chemistry analyzer (Boehringer Mannheim, Germany). The HOMA-IR was used to assess patients with insulin resistance. HOMA-IR scores were calculated by the following equation: [fasting insulin level (uU/mL)] × [fasting glucose level (mmol/L)]/22.5. HOMA-IR values were log-transformed due to their non-normal distribution. Subsequently, the log-transformed HOMA-IR values were categorized into quartiles (< 0.23, 0.23–0.36, 0.36–0.53, and > 0.53).

**Clinical and laboratory variables.** Baseline demographics and previous history of hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, peripheral artery disease, or cardiac arrhythmia were collected in all patients. Routine blood tests; chest X-rays; 12-lead electrocardiograms; transthoracic echocardiography; and brain imaging data, including computed tomography (CT), magnetic resonance imaging (MRI), and cerebral angiographic study using CT or/and MRI, were performed. Stroke severity was assessed by the National Institutes of Health Stroke Scale (NIHSS) scores, and the Trial of Org 10,172 in Acute Stroke Treatment (TOAST) classification was used to determine the subtypes of stroke etiology24. To assess the clinical course, the presence of END, defined as an increase in NIHSS score more than 2 points during admission, was collected. Functional outcome 3 months after the stroke onset was assessed through outpatient visits or centralized telephone follow-ups. Patient follow-ups were processed by a physician or a well-trained stroke nurse using a standardized interview protocol. Poor functional outcome was defined as a score of 3 or more on the mRS score.

**Statistical analysis.** All statistical analyses were performed using SPSS (version 23.0, IBM Corp., Armonk NY, USA). The baseline characteristics were compared using Chi-squared ($\chi^2$) tests, independent t-tests, and analysis of variance (ANOVA) tests, as appropriate. The crude OR with 95% confidence intervals (CIs) for poor functional outcomes at 3 months were estimated by using the logistic regression model. The multivariable logistic regression model was used to further evaluate the relationship between HOMA-IR values and poor functional outcome. A two-tailed $p$-value of less than 0.05 was considered significant.

**Ethics approval and consent to participate.** This study was approved by the Korea University of College of Medicine Institutional Review Board. Informed consent of study participants was waived because of the retrospective study design. All methods were performed by the relevant guidelines and regulations.

**Results**

**Demographics and comparison of patients according to log HOMA-IR scores.** The mean age of the patients was 65.3 ± 13.5 years, and 65.2% were male. The median HOMA-IR value was 2.31 (interquartile range 1.68–3.42). When comparing patients according to the log HOMA-IR values divided into quartiles, age, fasting blood glucose levels, body mass index (BMI), lipid levels, and hemoglobin A1c values differed between
quartiles. The highest quartile patients tended to be younger and had higher fasting blood glucose, total cholesterol, triglycerides, low-density lipoprotein, and hemoglobin A1c levels (Table 1). The presence of early neurological deterioration (END) was not different between the groups. There was no statistical difference in the rate of poor prognosis among the log HOMA-IR quartiles. Still, the modified Rankin Scale (mRS) score distribution showed a tendency of higher mRS score distributions in the highest quartile (Fig. 2).

Association between log HOMA-IR values and short-term prognosis after ischemic stroke. Of all the subjects, 25.9% had poor prognoses. Table 2 shows a comparison of patients according to their prognosis 3 months after an acute ischemic stroke. The log HOMA-IR values were higher in patients with poor prognoses \((p = 0.06)\). After adjustment for age, sex, and variables with \(p\)-values < 0.1 in univariate analysis, the log HOMA-IR scores were independently associated with poor prognosis (odds ratios (OR) = 3.877, 95% CI 1.461—10.288, \(p = 0.006\)) (Table 2). Subgroup analysis was performed on the severity of stroke (NIHSS score 0–8, ≥ 9), time of

| HOMA-IR, quartiles | Q1 (n = 129) | Q2 (n = 132) | Q3 (n = 128) | Q4 (n = 128) | p-value |
|--------------------|-------------|-------------|-------------|-------------|---------|
| Age (years)        | 67.7 ± 14.2 | 65.9 ± 11.0 | 64.8 ± 13.2 | 62.6 ± 13.1 | 0.001   |
| Male sex           | 79 (61.2)   | 91 (68.9)   | 80 (62.5)   | 87 (68.0)   | 0.467   |
| Hypertension       | 58 (45.0)   | 70 (53.0)   | 73 (57.0)   | 72 (56.2)   | 0.194   |
| Previous coronary artery disease | 6 (4.7) | 13 (9.8) | 9 (7.0) | 9 (7.0) | 0.446 |
| Previous stroke    | 11 (8.5)    | 15 (11.4)   | 13 (10.2)   | 9 (7.0)     | 0.648   |
| Body mass index (kg/m²) | 22.6 ± 2.9 | 24.0 ± 2.7  | 24.2 ± 4.1  | 25.2 ± 3.5  | <0.001  |
| Fasting blood glucose (mg/dL) | 93.1 ± 10.5 | 100.0 ± 13.9 | 107.2 ± 23.0 | 120.7 ± 26.1 | <0.001  |
| Total cholesterol level (mg/dL) | 184.2 ± 37.5 | 188.9 ± 42.0 | 191.5 ± 37.6 | 196.0 ± 40.4 | 0.015   |
| Triglycerides level (mg/dL) | 101.8 ± 54.1 | 123.4 ± 72.6 | 136.2 ± 87.8 | 154.0 ± 116.6 | <0.001  |
| High-density lipoprotein cholesterol (mg/dL) | 47.8 ± 12.9 | 46.2 ± 12.4 | 42.5 ± 10.0 | 44.9 ± 10.6 | 0.006   |
| Low-density lipoprotein cholesterol (mg/dL) | 106.8 ± 32.3 | 114.8 ± 37.0 | 117.1 ± 32.9 | 117.6 ± 33.6 | 0.029   |
| Hemoglobin A1c (%) | 5.5 ± 0.4    | 5.6 ± 0.4    | 5.6 ± 0.4    | 5.7 ± 0.4    | 0.001   |
| Systolic blood pressure (mmHg) | 150.5 ± 28.2 | 150.3 ± 28.6 | 150.5 ± 29.6 | 149.1 ± 28.4 | 0.723   |
| Diastolic blood pressure (mmHg) | 89.3 ± 13.6 | 88.0 ± 15.5 | 87.5 ± 16.0 | 89.7 ± 16.5 | 0.912   |
| Initial NIHSS score, median (IQR) | 3 (1–6) | 2 (1–5) | 3 (1–5) | 3 (1–6) | 0.146   |
| TOAST classification subtype | | | | | 0.953 |
| Large artery atherosclerosis | 30 (23.3) | 32 (24.2) | 37 (28.9) | 43 (33.6) | |
| Cardioembolism       | 40 (31.0)   | 23 (17.4)   | 18 (14.1)   | 20 (15.6)   | |
| Small vessel occlusion | 25 (19.4) | 39 (29.5) | 37 (28.9) | 25 (19.5) | |
| Undetermined         | 28 (21.7)   | 29 (22.0)   | 31 (24.2)   | 31 (24.2)   | |
| Others               | 6 (4.7)     | 9 (6.8)     | 5 (3.9)     | 9 (7.0)     | |
| Early neurological deterioration | 4 (3.1) | 12 (9.1) | 6 (4.7) | 8 (6.2) | 0.197 |
| Poor neurological outcome at 3 months | 30 (23.3) | 29 (22) | 34 (26.6) | 41 (32.0) | 0.254 |

Table 1. Baseline characteristics according to log homeostasis model assessment of insulin resistance scores quartiles. Data are expressed as the mean ± SD, or n (%). HOMA-IR, homeostasis model assessment of insulin resistance scores; NIHSS, National Institutes of Health Stroke Scale (NIHSS); IQR, interquartile range; TOAST, the Trial of Org 10,172 in Acute Stroke Treatment.

Figure 2. Modified Rankin Scale score distribution according to log homeostasis model assessment of insulin resistance score quartiles. Modified Rankin Scale score distribution shows higher score distributions in the highest quartile of log homeostasis model assessment of insulin resistance scores.
Scientific Reports | (2022) 11:1229 | https://doi.org/10.1038/s41598-020-80315-z

Discussion

Our study showed that log HOMA-IR scores were significantly associated with non-diabetic ischemic stroke patients’ poor functional outcome. This association remained statistically significant even the age of the highest quartiles of log HOMA-IR was youngest among quartiles, and the relationship was sustained after adjusting for cardiovascular risk factors and lipid profile abnormalities.

The most significant factors influencing stroke prognosis are the severity of the initial stroke severity and worsening of neurologic symptoms. But in this study, the initial stroke severity and the presence of END were not different between the HOMA-IR quartiles. Additionally, no interaction was observed in the subgroup analysis for stroke severity and log HOMA IR. These results indicate that the detrimental effects of insulin resistance affect the recovery phase of acute ischemic stroke and are not associated with exacerbating pre-existing disability. Since insulin resistance has been known to affect neuroplasticity in patients with diabetes, our study result is in line with previous studies. A recent registry-based cohort study in Japan also reported that HOMA-IR scores were related to the poor functional outcome at 1 year. They showed no associations between insulin resistance and recurrent stroke or mortality. Since we hypothesized that insulin resistance affects recovery after stroke, these results align with our study. Meanwhile, another study in China reported that the HOMA-IR index scores were associated with increased mortality, recurrent stroke, and short-term poor outcomes. The differences between the study results may be due to different study populations.

Some hypotheses may explain the association between insulin resistance and poor patient outcome after an ischemic stroke. One of them involves the concept of synaptic plasticity. Synaptic plasticity is a neuron’s ability to change the synapse in response to external stimuli and activity. In the brain, the insulin/IGF receptor signaling pathway maintains the balance between neuroprotective and neurotoxic effects. Insulin resistance is defined as a loss of this function in insulin ligands. Subsequently, when the balance is broken, it causes changes in the neurons’ survival and synaptic plasticity. Likewise, the brain’s synaptic plasticity decreases in stroke patients with high insulin resistance, which interferes with its recovery from the primary insult. Second, insulin resistance in
muscles may have contributed to the poor prognosis of these patients. Type 2 diabetes mellitus patients evolve whole-body insulin resistance, and insulin resistance in skeletal muscles reduces glucose transport pathways, which results in excessive reactive oxygen species and mitochondrial dysfunction30,31. This may interrupt recovery after an acute ischemic stroke. Third, endothelial damage might play a role. Endothelial function is related to vascular reactivity in the cerebral circulation31. Insulin and insulin resistance affect vascular endothelium31–33. Furthermore, insulin resistance is a risk factor for atherosclerosis34,35. Endothelial dysfunctions, decreased vascular reactivity, and enhanced atherosclerosis might cause recurrent stroke and delayed restoration of function.

Our study had some strengths. First, we demonstrated that the worsening effect of insulin resistance on ischemic stroke impacted the recovery phase. This finding indicates that we should treat insulin resistance itself, apart from diabetes mellitus, especially in the subacute stage of an acute ischemic stroke. Second, unlike previous ischemic stroke, impacted the recovery phase. This finding indicates that we should treat insulin resistance itself, apart from diabetes mellitus, especially in the subacute stage of an acute ischemic stroke. Furthermore, insulin resistance is a risk factor for atherosclerosis34,35. Endothelial dysfunctions, decreased vascular reactivity, and enhanced atherosclerosis might cause recurrent stroke and delayed restoration of function.

Conclusion
Insulin resistance measured by the HOMA-IR index was associated with the poor functional outcome of nondiabetic stroke patients. This finding may strengthen the need to treat insulin resistance itself in acute ischemic stroke patients with blood glucose levels within the normal range.

Received: 1 April 2020; Accepted: 17 November 2020
Published online: 13 January 2021

References
1. Kahn, S. E. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J. Clin. Endocrinol. Metab. 86, 4047–4058. https://doi.org/10.1210/jcem.86.9.7713 (2001).
2. Bergman, R. N. & Ader, M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol. Metab. 11, 351–356 (2000).
3. Matthews, D. R. et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).
4. Gao, C., Liu, Y., Li, L. & Hölscher, C. New animal models of Alzheimer’s disease that display insulin desensitization in the brain. Rev. Neurosci. 24, 607–615. https://doi.org/10.1515/reneuro-2013-0034 (2013).
5. Stoecckl, L. E. et al. Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunctions. F1000Research 5, 353. https://doi.org/10.12688/f1000research.8300.2 (2016).
6. de la Monte, S. M. Insulin resistance and Alzheimer's disease. BMJ Rep. 42, 475–481. https://doi.org/10.5438/bmirep.2009.42.8.475 (2009).
7. Teixeira, M. M. et al. Association between diabetes and cognitive function at baseline in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Sci. Rep. 10, 1596. https://doi.org/10.1038/s41598-020-58332-9 (2020).
8. Ott, A. et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937–1942. https://doi.org/10.1212/wnl.53.9.1937 (1999).
9. Biessels, G. J., Stakenborg, S., Brunner, E., Brayne, C. & Scheltens, P. Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol. 5, 64–74. https://doi.org/10.1016/S1474-4422(05)70284-2 (2006).
10. Brüning, J. C. et al. Role of brain insulin receptor in control of body weight and reproduction. Science 289, 2122–2125. https://doi.org/10.1126/science.289.5487.2122 (2000).
11. Lin, X. et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J. Clin. Investig. 114, 908–916. https://doi.org/10.1172/JCI22217 (2004).
12. Grillo, C. A. et al. Hippocampal insulin resistance impairs spatial learning and synaptic plasticity. Diabetes 64, 3927–3936. https://doi.org/10.2337/db15-0596 (2015).
13. Lindsberg, P. J. & Roine, R. O. Hyperglycemia in acute stroke. Stroke 35, 363–364. https://doi.org/10.1161/01.STR.0000115297.92132.84 (2004).
14. Savopoulou, C. et al. Loss of hyperglycemia in acute phase stroke still a dilemma?. J. Endocrinol. Investig. 40, 457–462. https://doi.org/10.1007/s40618-016-0584-8 (2017).
15. Powers, W. J. et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 50, e344–e418. https://doi.org/10.1161/strokeaha.119.022111 (2019).
16. Bas, D. E., Ondemir, A. O., Golak, E. & Kebapci, N. Higher insulin resistance level is associated with worse clinical response in acute ischemic stroke patients treated with intravenous thrombolysis. Transl. Stroke Res. 7, 167–171. https://doi.org/10.1007/s12975-016-0453-y (2016).
17. Calleja, A. I. et al. Insulin resistance is associated with a poor response to intravenous thrombolysis in acute ischemic stroke. Diabetes Care 34, 2413–2417. https://doi.org/10.2337/dc11-1242 (2011).
18. Kornan, W. N. et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 34, 1431–1436. https://doi.org/10.1161/str.01.000000000000234.0 (2003).
19. Kornan, W. N. et al. Pioglitazone after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 374, 1321–1331. https://doi.org/10.1056/NEJMoa1506930 (2016).
20. Sa-Vigamoon, P. et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol. Appl. Pharmacol. 333, 43–50. https://doi.org/10.1016/j.taap.2017.08.005 (2017).
21. Han, S. et al. Dagaprilflizion, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723–1729. https://doi.org/10.2337/db07-1472 (2008).
22. Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. *Lancet* 393, 31–39. https://doi.org/10.1016/s0140-6736(18)32590-x (2019).

23. Jing, J. et al. Insulin resistance and prognosis of nondiabetic patients with ischemic stroke: The ACROSS-China Study (abnormal glucose regulation in patients with acute stroke across China). *Stroke* 48, 887–893. https://doi.org/10.1161/strokeaha.116.015613 (2017).

24. Adams, H. P. Jr. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. *Trial of Org 10172 in acute stroke treatment*. *Stroke* 24, 35–41 (1993).

25. Ago, T. et al. Insulin resistance and clinical outcomes after acute ischemic stroke. *Neurology* 90, e1470–e1477. https://doi.org/10.1212/wnl.0000000000005358 (2018).

26. Tamaguchi, F. et al. Insulin-like growth factor I (IGF-I) distribution in the tissue and extracellular compartment in different regions of rat brain. *Brain Res.* 533, 344–347 (1990).

27. Raskin, D. G., Figlewicz, D. P., Woods, S. C., Porte, D. Jr. & Dorsa, D. M. Insulin in the brain. *Annu. Rev. Physiol.* 49, 335–347. https://doi.org/10.1146/annurev.ph.49.030187.002003 (1987).

28. Le Roith, D. et al. Insulin in brain and other extrapancreatic tissues of vertebrates and nonvertebrates. *Adv. Metab. Disord.* 10, 303–340 (1983).

29. Zierath, J. R., Krook, A. & Wallberg-Henriksson, H. Insulin action and insulin resistance in human skeletal muscle. *Diabetologia* 43, 821–835. https://doi.org/10.1007/s001250051457 (2000).

30. Di Meo, S., Iossa, S. & Venditti, P. Skeletal muscle insulin resistance: Role of mitochondria and other ROS sources. *J. Endocrinol.* 233, R15–R42. https://doi.org/10.1530/joe-16-0598 (2017).

31. Prakash, K., Chandran, D. S., Khadgawat, R., Jaryal, A. K. & Deepak, K. K. Correlations between endothelial function in the systemic and cerebral circulation and insulin resistance in type 2 diabetes mellitus. *Diabetes Vasc. Dis. Res.* 13, 49–55. https://doi.org/10.1177/1747164115604120 (2016).

32. Muniyappa, R. & Quon, M. J. Insulin action and insulin resistance in vascular endothelium. *Curr. Opin. Clin. Nutr. Metab. Care* 10, 523–530. https://doi.org/10.1097/MCO.0b013e32819f8ec4 (2007).

33. Hseuh, W. A. & Law, R. E. Insulin signaling in the arterial wall. *Am. J. Cardiol.* 84, 21j–24j (1999).

34. Sourij, H. et al. Insulin resistance as a risk factor for carotid atherosclerosis: A comparison of the Homeostasis Model Assessment and the short insulin tolerance test. *Stroke* 39, 1349–1351. https://doi.org/10.1161/strokeaha.107.502799 (2008).

35. Gage, M. C. et al. Endothelium-specific insulin resistance leads to accelerated atherosclerosis in areas with disturbed flow patterns: A role for reactive oxygen species. *Atherosclerosis* 230, 131–139. https://doi.org/10.1016/j.atherosclerosis.2013.06.017 (2013).

Acknowledgements
This study is supported by Korea University R&D Support Program (K1912701) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF-2020R1C1C1013304).

Author contributions
Y.C., C.K.K. and K.O. contributed to conception and design of the study, Y.C. and C.K.K. analyzed and interpreted the patient data. Y.C. and C.K.K. drafted the manuscript. M.K., W.K.S. and K.O. critically revised the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-020-80315-z.

Correspondence and requests for materials should be addressed to K.O.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021